Back to search

Peptide record

TPDB25481

Antibacterial Toxicity modified_plain modified
3 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB25481
Antibacterial Toxicity
Anti-infective peptides Toxicity and safety peptides
Peptipedia
modified_plain
Yes
A 3-aa modified multi-activity (Antibacterial and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Modified, details unspecified
Sequence
RXR
Physicochemical Analysis
C12H26N8O3
ANDCEQGHILKMFPSTWYV
R
330.39
12.40
2
0
0
+2
1.62
-3.000
0.00
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
0
0.00
0
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
0
L
0
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
3
C12H26N8O3
330.39
12.40
+2
1.62
-3.000
Evidence Records 27 records
Evidence 1 Activity

Activity

50% Hemolysis
Toxicity
>1000 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >1000 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Design and synthesis of oligo-lipidated arginyl peptide (OLAP) dimers with enhanced physicochemical activity, peptide stability and their antimicrobial actions against MRSA infections. | Amino Acids | 2018
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
411.2±43.6 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 411.2±43.6 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Design and synthesis of oligo-lipidated arginyl peptide (OLAP) dimers with enhanced physicochemical activity, peptide stability and their antimicrobial actions against MRSA infections. | Amino Acids | 2018
Evidence 3 Activity

Activity

50% Hemolysis
Toxicity
707.5±29.2 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 707.5±29.2 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Design and synthesis of oligo-lipidated arginyl peptide (OLAP) dimers with enhanced physicochemical activity, peptide stability and their antimicrobial actions against MRSA infections. | Amino Acids | 2018
Evidence 4 Activity

Activity

50% Hemolysis
Toxicity
158.4±36.3 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 158.4±36.3 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Design and synthesis of oligo-lipidated arginyl peptide (OLAP) dimers with enhanced physicochemical activity, peptide stability and their antimicrobial actions against MRSA infections. | Amino Acids | 2018
Evidence 5 Activity

Activity

10% Hemolysis
Toxicity
36 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 36 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
De novo design and synthesis of ultra-short peptidomimetic antibiotics having dual antimicrobial and anti-inflammatory activities. | PLoS One | 2013
Evidence 6 Activity

Activity

10% Hemolysis
Toxicity
>256 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | >256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
De novo design and synthesis of ultra-short peptidomimetic antibiotics having dual antimicrobial and anti-inflammatory activities. | PLoS One | 2013
Evidence 7 Activity

Activity

50% Hemolysis
Toxicity
364.17±105.10 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 364.17±105.10 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Glycosylated Lipopeptides-Synthesis and Evaluation of Antimicrobial Activity and Cytotoxicity | Biomolecules | 2023
Evidence 8 Activity

Activity

IC50
Toxicity
25.16±3.47 µg/mL
Cytotoxic
IC50 | 25.16±3.47 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Glycosylated Lipopeptides-Synthesis and Evaluation of Antimicrobial Activity and Cytotoxicity | Biomolecules | 2023
Evidence 9 Activity

Activity

IC50
Toxicity
14.08±3.48 µg/mL
Cytotoxic
IC50 | 14.08±3.48 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Glycosylated Lipopeptides-Synthesis and Evaluation of Antimicrobial Activity and Cytotoxicity | Biomolecules | 2023
Evidence 10 Activity

Activity

50% Hemolysis
Toxicity
73.34±1.63 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 73.34±1.63 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Glycosylated Lipopeptides-Synthesis and Evaluation of Antimicrobial Activity and Cytotoxicity | Biomolecules | 2023
Evidence 11 Activity

Activity

50% Hemolysis
Toxicity
45.25±0.59 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 45.25±0.59 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Glycosylated Lipopeptides-Synthesis and Evaluation of Antimicrobial Activity and Cytotoxicity | Biomolecules | 2023
Evidence 12 Activity

Activity

IC50
Toxicity
9.45±0.89 µg/mL
Cytotoxic
IC50 | 9.45±0.89 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Glycosylated Lipopeptides-Synthesis and Evaluation of Antimicrobial Activity and Cytotoxicity | Biomolecules | 2023
Evidence 13 Activity

Activity

Toxicity
Hemolytic
NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
J Med Chem | 2008
Evidence 14 Activity

Activity

50% Hemolysis
Toxicity
705 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 705 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Synthetic antimicrobial peptidomimetics with therapeutic potential. | J Med Chem | 2008
Evidence 15 Activity

Activity

50% Hemolysis
Toxicity
90 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 90 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Synthetic antimicrobial peptidomimetics with therapeutic potential. | J Med Chem | 2008
Evidence 16 Activity

Activity

4.23% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
4.23% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial Peptides Incorporating Halogenated Marine-Derived Amino Acid Substituents. | ACS Med Chem Lett | 2023
Evidence 17 Activity

Activity

50% Hemolysis
Toxicity
175 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 175 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption | J Med Chem | 2011
Evidence 18 Activity

Activity

0.29% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
0.29% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial Peptides Incorporating Halogenated Marine-Derived Amino Acid Substituents. | ACS Med Chem Lett | 2023
Evidence 19 Activity

Activity

0.34% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
0.34% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial Peptides Incorporating Halogenated Marine-Derived Amino Acid Substituents. | ACS Med Chem Lett | 2023
Evidence 20 Activity

Activity

0.4% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
0.4% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial Peptides Incorporating Halogenated Marine-Derived Amino Acid Substituents. | ACS Med Chem Lett | 2023
Evidence 21 Activity

Activity

1.38% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
1.38% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial Peptides Incorporating Halogenated Marine-Derived Amino Acid Substituents. | ACS Med Chem Lett | 2023
Evidence 22 Activity

Activity

1.62% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
1.62% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial Peptides Incorporating Halogenated Marine-Derived Amino Acid Substituents. | ACS Med Chem Lett | 2023
Evidence 23 Activity

Activity

1.19% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
1.19% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial Peptides Incorporating Halogenated Marine-Derived Amino Acid Substituents. | ACS Med Chem Lett | 2023
Evidence 24 Activity

Activity

0% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Discovery of novel histidine-derived lipo-amino acids: applied in the synthesis of ultra-short antimicrobial peptidomimetics having potent antimicrobial activity, salt resistance and protease stability | Eur J Med Chem | 2013
Evidence 25 Activity

Activity

50% Hemolysis
Toxicity
121 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 121 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Discovery of novel histidine-derived lipo-amino acids: applied in the synthesis of ultra-short antimicrobial peptidomimetics having potent antimicrobial activity, salt resistance and protease stability | Eur J Med Chem | 2013
Evidence 26 Activity

Activity

50% Hemolysis
Toxicity
>256 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Discovery of novel histidine-derived lipo-amino acids: applied in the synthesis of ultra-short antimicrobial peptidomimetics having potent antimicrobial activity, salt resistance and protease stability | Eur J Med Chem | 2013
Evidence 27 Activity

Activity

10% Hemolysis
Toxicity
>256
Hemolytic Cytotoxic
10% Hemolysis | >256 | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Non hemolytic short peptidomimetics as a new class of potent and broad-spectrum antimicrobial agents. | Bioorg Med Chem Lett | 2013